Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)

Phase 3 Completed 756 enrolled Center for Research and Production of Vaccines and Biologicals, Vietnam Vietnam Military Medical University · collab

RandomizedParallel-groupSingle-blindPrevention

Summary

The study is conducted to evaluate the safety and Immunogenicity of Measles-Rubella combined vaccine MRVAC produced by POLYVAC (phase 3) on Vietnamese volunteers and to demonstrate non-inferiority on the immunogenicity of MRVAC in comparison to MR vaccine produced by Serum Institute, India.

Timeline

Start: 2016-04
Primary completion: 2016-07
Completion: 2016-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	MR vaccine	Vaccine	—	Subcutaneous
Comparator	MRVAC	Vaccine	0.5 ml	Subcutaneous

Indications

No indication recorded.